TB
The startup develops oral drug delivery technology that utilizes lymphatic system targeting to enhance the distribution of small-molecule drugs. This approach aims to improve the efficacy and safety of treatments for conditions with significant unmet medical needs.
Updated 3 months ago
Funding
$960K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops oral drug delivery technology that utilizes lymphatic system targeting to enhance the distribution of small-molecule drugs. This approach aims to improve the efficacy and safety of treatments for conditions with significant unmet medical needs.